

8 December 2014  
ASX Release

## **Actinogen Limited (ASX Code: ACW)**

### **Change of Address Details**

Actinogen Limited (**the Company**) wishes to notify that the Company has changed address and contact details as follows:

#### **Registered Office Address:**

Level 10, 15-17 Young Street  
SYDNEY NSW 2000

#### **Principal Office Address:**

Level 10, 15-17 Young Street  
SYDNEY NSW 2000

#### **Contact Details:**

Phone: + 61 2 9251 5620

Peter Webse  
Company Secretary  
**Actinogen Limited**

#### **About Actinogen Limited** Actinogen Limited (ASX: ACW)

Actinogen is a clinical stage Australian biotechnology company focused on the development of novel treatments for Alzheimer's Disease (AD) and other major age-related neurodegenerative disorders. Actinogen's lead candidate UE2343 is a small molecule inhibitor of 11-beta-hydroxysteroid dehydrogenase (11 $\beta$ -HSD1) an enzyme that reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. There is evidence for a role of glucocorticoids and hypothalamus-pituitary-adrenal axis dysfunction in AD that includes both cortisol-induced neurotoxicity on the hippocampal formation and acute ongoing impairment of cognition. UE2343 was discovered in 2007 at the laboratory of Professor Brian Walker at the University of Edinburgh. Supported by The Wellcome Trust, the University has spent approximately \$25M AUD for the development of UE2343.

In addition, the Company has an early stage drug discovery program focused on developing drugs to treat brain cancer and potentially other oncological diseases by the targeted killing of cancer stem cells (CSCs). The first study was conducted in collaboration with Curtin University and the results demonstrated substantial reduction of proliferation in CSCs populations in glioblastoma cell lines.